Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract
Annals of Oncology, 04/04/2012Seront E et al.
Everolimus showed clinical activity in advanced transitional carcinoma cell (TCC). The profile of the plasma angiogenesis–related proteins suggested a role of the everolimus antiangiogenic properties in disease control. PTEN loss might be associated with everolimus resistance.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.